Literature DB >> 18451669

Oxidative stress in hemodialysis.

Jonathan Himmelfarb1.   

Abstract

Patients with advanced chronic kidney disease are at a greatly increased cardiovascular risk that cannot be explained entirely by traditional cardiovascular risk factors. An increase in oxidative stress is proposed as a non-traditional cardiovascular risk factor in this patient population. Many laboratories have now unequivocally demonstrated that uremia is an increased oxidative stress state. Uremic oxidative stress is characterized biologically by an increase in lipid peroxidation products and reactive aldehyde groups as well as by increased retention of oxidized thiols. The pathophysiology of increased oxidative stress in uremia is multifactorial, but the retention of oxidized solute by the loss of kidney function is probably a major contributor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18451669     DOI: 10.1159/000130658

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  15 in total

1.  LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.

Authors:  Wanghui Jing; Nosratola D Vaziri; Ane Nunes; Yasunori Suematsu; Ted Farzaneh; Mahyar Khazaeli; Hamid Moradi
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK).

Authors:  Jamison Chang; Jennie Z Ma; Qing Zeng; Sylvia Cechova; Adam Gantz; Caroline Nievergelt; Daniel O'Connor; Michael Lipkowitz; Thu H Le
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-05

3.  Biochemical oxidative stress-related markers in patients with obstructive sleep apnea.

Authors:  Jana Volná; David Kemlink; Marta Kalousová; Jana Vávrová; Veronika Majerová; Otto Mestek; Jana Svarcová; Karel Sonka; Tomás Zima
Journal:  Med Sci Monit       Date:  2011-09

4.  The blood compatibilities of blood purification membranes and other materials developed in Japan.

Authors:  Takaya Abe; Karen Kato; Tomoaki Fujioka; Tadao Akizawa
Journal:  Int J Biomater       Date:  2011-09-28

Review 5.  Prognostic effect of high-flux hemodialysis in patients with chronic kidney disease.

Authors:  X Li; H Xu; X C Xiao; S L Deng; W Wang; R Tang
Journal:  Braz J Med Biol Res       Date:  2015-11-27       Impact factor: 2.590

6.  High density lipoprotein (HDL) particles from end-stage renal disease patients are defective in promoting reverse cholesterol transport.

Authors:  Josephine L C Anderson; Thomas Gautier; Niels Nijstad; Markus Tölle; Mirjam Schuchardt; Markus van der Giet; Uwe J F Tietge
Journal:  Sci Rep       Date:  2017-02-02       Impact factor: 4.379

7.  Protein Carbonyl Content Is a Predictive Biomarker of Eccentric Left Ventricular Hypertrophy in Hemodialysis Patients.

Authors:  Zorica M Dimitrijevic; Sonja S Salinger Martinovic; Valentina N Nikolic; Tatjana P Cvetkovic
Journal:  Diagnostics (Basel)       Date:  2019-11-25

8.  Venous versus arterial iron administration in haemodialysis. Influence on erythrocytes antioxidant parameters.

Authors:  C B Dogaru; C Capusa; L Gaman; E Torac; D Lixandru; M Gilca; L Iosif; C Muscurel; I Stoian; G Mircescu; V Atanasiu
Journal:  J Med Life       Date:  2015

9.  Novel PAradigm to improve Inflammatory burden in end stage Renal disease (rePAIR): study protocol for a randomized controlled trial.

Authors:  Ruchir Trivedi; George Fares; Victoria Barany Nunez; Ryan Campbell; Megyn Clement; Joseph Burleson; Jonathan Himmelfarb; Effie Ioannidou
Journal:  Trials       Date:  2018-07-11       Impact factor: 2.279

10.  The HSP72 stress response of monocytes from patients on haemodialysis is impaired.

Authors:  Stefan Reuter; Philip Bangen; Bayram Edemir; Uta Hillebrand; Hermann Pavenstädt; Stefan Heidenreich; Detlef Lang
Journal:  Nephrol Dial Transplant       Date:  2009-04-01       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.